BVF 068Alternative Names: BVF-068
Latest Information Update: 10 Mar 2010
At a glance
- Originator Pharma Pass II LLC
- Developer Biovail Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 07 Nov 2007 Preclinical trials in CNS disorders in USA (unspecified route)